Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Aug;56(2):123–126. doi: 10.1038/bjc.1987.168

Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM).

R Raijmakers 1, P Speth 1, T de Witte 1, P Linssen 1, J Wessels 1, C Haanen 1
PMCID: PMC2002152  PMID: 3663464

Abstract

The effect of adriamycin (ADM) infusion-rate on cellular ADM concentrations and on clonogenicity of human haematopoietic cells was studied in vivo and in vitro. In patients an ADM dose of 30 mg m-2 was administered as a bolus injection, or as a 4 h or a 24 h infusion. In vitro the effect of ADM on clonogenic cell growth was determined after exposure during 5 min, 2 h and 24 h of human bone marrow cells to increasing ADM concentrations. ADM showed rapid intracellular accumulation, to levels 100-fold the plasma concentration in vivo or the incubation medium concentration in the in vitro experiments. After a bolus injection or 5 min exposure only approximately 10% of the cellular peak ADM was retained after elimination of the drug from the plasma or the incubation medium. Ninety percent of the ADM was apparently 'loosely' bound. After 4 h and 24 h constant-rate infusions and also after 2 h and 24 h incubations in vitro, the cells accumulated ADM gradually, and the subsequent washing-out of the cellular ADM was substantially less, most of the ADM being 'tightly' bound. Despite these different patterns of uptake and retention after in vivo short- and long-lasting infusion of the same total dose, the 'tightly-bound' cellular ADM concentrations were the same. Moreover, comparable cellular ADM concentrations, retained after efflux of the 'loosely-bound' cellular ADM fraction were equally cytotoxic to normal human clonogenic cells. Short-lasting cellular peak ADM concentrations which occur after a bolus injection or after short exposure to high ADM concentrations are not essential for the cytotoxic effect, in contrast to the retained, 'tightly-bound' cellular ADM levels.

Full text

PDF
123

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson B., Beran M., Peterson C., Tribukait B. Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin. Cancer Res. 1982 Jan;42(1):178–183. [PubMed] [Google Scholar]
  2. Bailey-Wood R., Dallimore C. M., Whittaker J. A. Effect of adriamycin on CFUGM at plasma concentrations found following therapeutic infusions. Br J Cancer. 1984 Sep;50(3):351–355. doi: 10.1038/bjc.1984.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Garnick M. B., Weiss G. R., Steele G. D., Jr, Israel M., Schade D., Sack M. J., Frei E., 3rd Clinical evaluation of long-term, continuous-infusion doxorubicin. Cancer Treat Rep. 1983 Feb;67(2):133–142. [PubMed] [Google Scholar]
  4. Legha S. S., Benjamin R. S., Mackay B., Ewer M., Wallace S., Valdivieso M., Rasmussen S. L., Blumenschein G. R., Freireich E. J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb;96(2):133–139. doi: 10.7326/0003-4819-96-2-133. [DOI] [PubMed] [Google Scholar]
  5. Lewis J. P., Meyers F. J., Tanaka L. Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukaemia. Br J Haematol. 1985 Oct;61(2):261–265. doi: 10.1111/j.1365-2141.1985.tb02824.x. [DOI] [PubMed] [Google Scholar]
  6. Nguyen-Ngoc T., Vrignaud P., Robert J. Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors. Oncology. 1984;41(1):55–60. doi: 10.1159/000225791. [DOI] [PubMed] [Google Scholar]
  7. Preisler H. D., Raza A. Uptake of adriamycin by human leukemic cells as measured by flow cytometry. Med Oncol Tumor Pharmacother. 1984;1(1):43–48. doi: 10.1007/BF02935324. [DOI] [PubMed] [Google Scholar]
  8. Skovsgaard T. Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem Pharmacol. 1978;27(8):1221–1227. doi: 10.1016/0006-2952(78)90455-0. [DOI] [PubMed] [Google Scholar]
  9. Speth P. A., Linssen P. C., Boezeman J. B., Wessels H. M., Haanen C. Quantitation of anthracyclines in human hematopoietic cell subpopulations by flow cytometry correlated with high pressure liquid chromatography. Cytometry. 1985 Mar;6(2):143–150. doi: 10.1002/cyto.990060210. [DOI] [PubMed] [Google Scholar]
  10. Speth P. A., Linssen P. C., Boezeman J. B., Wessels J. M., Haanen C. Rapid quantitative determination of four anthracyclines and their main metabolites in human nucleated haematopoietic cells. J Chromatogr. 1986 Apr 25;377:415–422. doi: 10.1016/s0378-4347(00)80803-8. [DOI] [PubMed] [Google Scholar]
  11. Speth P. A., Linssen P. C., de Pauw B. E., de Witte T. J. Cellular pharmacokinetics of daunomycin administered as continuous intravenous infusion in the treatment of acute non-lymphocytic leukaemia. Br J Haematol. 1986 Jul;63(3):602–605. doi: 10.1111/j.1365-2141.1986.tb07539.x. [DOI] [PubMed] [Google Scholar]
  12. Verma D. S., Spitzer G., Beran M., Zander A. R., McCredie K. B., Dicke K. A. Colony stimulating factor augmentation in human placental conditioned medium. Exp Hematol. 1980 Aug;8(7):917–923. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES